Testing a new eye injection for diabetic swelling
Part of Eyes & vision clinical trials.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have diabetic macular edema (DME) confirmed by eye imaging, with swelling thickness of at least 320 micrometers
- Have type 1 or type 2 diabetes that is being treated, with a recent blood sugar control measure (HbA1c) below 12%
- Be at least 18 years old and able to sign consent
- Have clear enough eye structures and ability to hold your eye still for imaging tests
- Have both eyes with adequate vision for daily functioning (not dependent on just one eye)
- If able to have children, agree to use effective birth control during the study; men should use condoms or abstain to prevent pregnancy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This trial tests a new medication, CU06-1004, for people with diabetic macular edema, a condition that causes blurry vision due to fluid buildup in the central part of the retina. The goal is to see if this drug can reduce the swelling and improve vision.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
This trial tests a more frequent dosing of an eye injection called pegaptanib (Macugen) to see if it can quickly reduce swelling in the retina caused by diabetes and improve vision. It is for people with diabetic macular edema who have some vision loss.
This trial tests whether a single steroid injection around the back of the eye can improve vision in people with diabetic macular edema (swelling in the center of the retina that blurs vision). It is for people who have not yet had any other eye treatments for this condition.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.